MedImmune Reaches for a Blockbuster

MedImmune Inc. is reaching for a blockbuster through its acquisition of Aviron, whose nasally inhaled flu vaccine FluMist now seems close to winning FDA approval--perhaps in time for the 2002 flu season. Aviron has struggled to develop the product, particularly with regulatory and marketing issues that MedImmune has shown it can handle well.